Oragenics reports ONP-002 stable across wide temperature range, eliminating cold storage needs for concussion drug

ORAGENICS INC

ONP-002 shows >99% purity after 3-month stability testing at -20°C to 104°C.
Drug-device combination designed for acute field-delivery without cumbersome cold chain logistics.
Phase II clinical trial batch synthesis completed; no FDA-approved pharmaceutical treatment currently exists for concussion.
Estimated 69 million concussions annually worldwide; drug targets intranasal delivery within minutes of injury.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.